Development of new therapeutic agents for inflammatory bowel disease based on the dendritic cell regulation via Dectin-1

• Project/Area Number: 22590697
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Shiga University of Medical Science
• Principal Investigator: FUJIYAMA Yoshihide 滋賀医科大学, 医学部, 教授 (70111896)
• Co-Investigator(Kenkyū-buntansha): ANDOH Akira 滋賀医科大学, 医学(系)研究科(研究院), 教授 (90252395) ; BAMBA Shigeki 滋賀医科大学, 医学部, 助教 (40422901)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 炎症性腸疾患 / Dectin-1 / schizophyllan / ドラッグデリバリーシステム / Schizophyllan / 遺伝子・デリバリー / 樹状細胞 / IL-23

Research Abstract

Dendritic cells are known to play an important role in inflammatory bowel diseases. Schizophyllan can be used as a transporter of DNA sequence into cytoplasm via Dectin-1 which is expressed on the surface of dendritic cells. We have investigated the application of this drug delivery system focusing on IL-23p19, IL-27p28 and NF-kB decoy. However, it was not possible to obtain sufficient suppression effect of experimental models of colitis.